The 2024 American Society of Clinical Oncology (ASCO) guidelines recommend that BRCA1/2 testing be offered to every patient newly diagnosed with breast cancer under 65 years, and selected patients over 65 moving towards universal testing [10]. This evidence concerns the gene BRCA1 and breast carcinoma.